ToposBio

At Gladstone, collaboration fuels discovery. Our partnership with @ToposBio brings together AI-powered protein modeling and deep expertise in neurodegenerative disease to explore new therapeutic options for conditions like Parkinson’s and Alzheimer’s. bit.ly/4sAewjD

Powered by @Modal compute; shout out to @charles_irl Excited to contribute to #DrugDesign #AI #Biology

Announcing Topos-1, an all-atom generative model that sets a new benchmark for predicting structural ensembles of intrinsically disordered proteins. Topos-1 outperforms existing models by a large margin, with implications for designing drugs for challenging targets ranging from cancer to neurodegenerative disease. Read the full technical report on our website: toposbio.ai/tech-report

Topos-1 is only the beginning: we’re rapidly expanding its capabilities and the favorable scaling results so far indicate a steep improvement curve. To learn more about the model and its evals, check out our technical report: toposbio.ai/tech-report

Using Topos-1, we generated conformational ensembles that provided drug design insight and lead to computational predictions of drug potency that are in good agreement with tests performed in our laboratory.